Organon & Company
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +3.07%.
Did OGN Beat Earnings? Q2 2025 Results
Organon delivered a modest beat across both top and bottom lines in Q2 2025, though the results did little to quiet growing concerns about the women's health and generics company's longer-term trajectory. Non-GAAP EPS came in at $1.00, clearing the $0.94 consensus estimate by 6.36%, while revenue of $1.59 billion edged past the $1.56 billion consensus by 2.32%, even as sales slipped 0.8% year over year. The primary engine behind the earnings beat was disciplined cost control, with non-GAAP adjusted EBITDA margin expanding to 32.7% from 31.9% a year earlier as restructuring efforts trimmed operating expenses by 3%. Fertility products surged 15% on a constant-currency basis, helping Women's Health partially offset softness in Nexplanon and continued pressure in Established Brands from European patent losses. Organon also raised its full-year revenue guidance midpoint by $100 million to a range of $6.28 billion to $6.38 billion, aided by a significantly reduced foreign exchange headwind; still, a class-action lawsuit alleging securities fraud has added a fresh layer of investor unease around the stock.
- Fertility business grew 15% ex-FX driven by Follistim AQ and geographic expansion
- Hadlima strong performance driving biosimilars growth of 6% ex-FX
- 3% reduction in operating expenses improving Adjusted EBITDA margin to 32.7%
- Vtama and Emgality partially offsetting Atozet LOE impact
- Nexplanon international growth of 10% ex-FX partially offsetting U.S. decline
- Pre-tax gain of $46 million from early extinguishment of debt
“During the quarter we paid down principal on our long-term debt and began implementing meaningful cost savings, which together set us on a path to achieve net leverage below 4.0x by the end of this year. We will aim to drive further improvement, with the goal of achieving net leverage of 3.5x or below by the end of 2026.”
Organon CEO, on the earnings call
Forward Guidance & Outlook
Organon raised its full-year 2025 revenue guidance to $6.275B–$6.375B (from $6.125B–$6.325B previously), reflecting nominal revenue growth of (2.0%) to (0.4%) and ex-FX revenue growth of (1.2%) to 0.3%. The FX translation headwind was reduced to approximately $50M from approximately $200M. Adjusted gross margin is expected at 60.0%–61.0%, SG&A in the mid-20% range, R&D at upper single-digit percentage of revenue, and Adjusted EBITDA margin of 31.0%–32.0% (all unchanged). The effective non-GAAP tax rate is guided at 22.5%–24.5%, with approximately 263M fully diluted weighted average shares outstanding. Interest expense is expected at approximately $510M and depreciation at approximately $135M. The company targets net leverage below 4.0x by year-end 2025 and 3.5x or below by end of 2026. Vtama is on track to deliver $150M of revenue for the full year. A potential U.S. denosumab biosimilar launch is expected in late 2025.
OGN YoY Financials
OGN Revenue by Segment
OGN Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.